{"id":1323,"date":"2025-11-20T08:18:55","date_gmt":"2025-11-20T08:18:55","guid":{"rendered":"https:\/\/sites.abo.fi\/madness\/?post_type=events&p=1323"},"modified":"2025-11-20T08:18:55","modified_gmt":"2025-11-20T08:18:55","slug":"frontiers-of-science-heterogeneity-in-cellular-senescence-from-mechanisms-to-interventions","status":"publish","type":"events","link":"https:\/\/sites.abo.fi\/madness\/events\/frontiers-of-science-heterogeneity-in-cellular-senescence-from-mechanisms-to-interventions\/","title":{"rendered":"Frontiers of Science: Heterogeneity in cellular senescence: from mechanisms to interventions"},"content":{"rendered":"\n

Frontiers of Science<\/strong><\/p>\n\n\n\n

11th<\/sup> December at 12:00
Onsite event
in Presidentti auditorium, BioCity
Autumn 2025 program<\/a><\/p>\n\n\n\n

Prof. Marco Demaria<\/strong>, University of Groningen, The Netherlands
Heterogeneity in cellular senescence: from mechanisms to interventions<\/em><\/p>\n\n\n\n

Host: Gennady Yegutkin (genyeg@utu.fi<\/a>)<\/p>\n\n\n\n

Coffee and sandwich served at 11:45, first come first serve!<\/p>\n\n\n\n

Six PhD researchers and early-career postdocs are welcome to have a lunch and discuss with Prof. Demaria <\/strong>after the seminar. This is a great possibility to learn hosting skills in a friendly environment and create connections for future. Everyone is welcome to join, BioCity Turku will offer the lunch.<\/p>\n\n\n\n

If you got interested, please send an email to biocityturku@bioscience.fi<\/a><\/p>\n\n\n\n

Dr Demaria is an associate professor in Cellular Ageing and his research is focused towards identifying novel mechanisms and biomarkers associated to senescent cells. His laboratory has also a strong interest to characterize the pro-disease functions of senescent cells induced during aging and by anti-cancer therapies. A major goal is to exploit these findings for the development of rejuvenating interventions. In 2018 he co-founded a start-up company, Cleara Biotech, devoted to develop anti-senescence drugs.<\/p>\n\n\n\n

Selected publications<\/strong><\/p>\n\n\n\n

Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer. Nehme J, Maassen S, Bravaccini S, Zanoni M, Gianni C, De Giorgi U, Soto-Gamez A, Altulea A, Gheorghe T, Wang B, Demaria M. EMBO J. 2025 Feb 10<\/p>\n\n\n\n

Guidelines for minimal information on cellular senescence experimentation in vivo. Ogrodnik M, Carlos Acosta J, Adams PD, d’Adda di Fagagna F, \u2026, Scharffetter-Kochanek K, Sedivy JM, Sikora E, Witwer K, von Zglinicki T, Yun MH, Grillari J, Demaria M. Cell. 2024 Aug 8;187(16):4150-4175<\/p>\n\n\n\n

Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury. Nehme J, Mesilmany L, Varela-Eirin M, Brandenburg S, Altulea A, Lin Y, Gaya da Costa M, Seelen M, Hillebrands JL, van Goor H, Saab R, Akl H, Prevarskaya N, Farfariello V, Demaria M.Nat Aging. 2024 Jun;4(6):771-782<\/p>\n\n\n\n

The Quest to Define and Target Cellular Senescence in Cancer. Wang B, Demaria M. Cancer Res. 2021 Dec 15;81(24):6087-6089.<\/p>\n\n\n\n

General information<\/strong><\/p>\n\n\n\n